Myocarditis Risk From COVID-19 Vaccines Up To 3 times Higher From Moderna Than Pfizer: Study
View Source | November 15, 2022 1:15 am
- Researchers pulled data from approximately 3 million people in British Columbia, Canada, and used participants over the age of 18 who were hospitalized for myocarditis, pericarditis, or myopericarditis within 21 days after having received a second Pfizer or Moderna between Jan. 1, 2021, and Sept. 9, 2021.
- The study excluded participants that had experienced myocarditis or pericarditis within one year before receiving the second dose of the COVID-19 vaccine.
- “Within 21 days of the second dose, there were a total of 59 myocarditis cases, 21 after Pfizer and 31 after Moderna; and there were a total of 41 pericarditis cases: 21 after Pfizer and 20 after Moderna,” the study reads.
Continue to Article
Share This Article: